Omeros Stock Sinks on Negative EU Opinion for Narsoplimab, Compassionate-Use Program Ends
Omeros shares are trading lower Friday after the company announced that the EMA’s CHMP upheld its negative opinion on narsoplimab for TA-TMA.
Share
Why It Matters
Omeros got bad news from European regulators about a medicine called narsoplimab. When a medicine gets rejected, investors worry the company will have less money from selling it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.